Scholarlink

Purpose <p>To evaluate the clinicopathological and prognostic significance of preoperative serum Midkine levels in patients with colorectal cancer.</p> Methods <p>Preoperative Midkine levels were analyzed using an enzyme-linked immunosorbent assay in 78 patients with colorectal cancer, at stages 0 (<i>n</i> = 2), I (<i>n</i> = 19), II (<i>n</i> = 25), III (<i>n</i> = 24), and IV (<i>n</i> = 8). Using a cut-off value of 421&#xa0;pg/mL, the patients were divided into a Midkine(+) group and a Midkine(−) group. Clinicopathological factors and prognosis were compared between the two groups, using univariate and multivariate analyses.</p> Results <p>The overall positive rates were 46%, 32%, and 21% for CEA, Midkine, and CA19-9, respectively. The positive rate of the Midkine/CEA combination was 55%. The positive rates at stage 0/I were 19%, 19%, and 5% for CEA, Midkine, and CA19-9, respectively. The Midkine(+) group showed poor survival, but the differences were not significant. The Midkine (+)/CEA (+) group had significantly worse relapse-free survival (RFS) (<i>p</i> = 0.02). The Midkine (+)/CEA (+) level was an independent risk factor for RFS (<i>p</i> = 0.04) and overall survival (<i>p</i> = 0.03).</p> Conclusion <p>The Midkine (+)/CEA (+) combination may be an indicator of poor prognosis for patients with colorectal cancer.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Association between the preoperative Midkine (+)/CEA (+) level and poor prognosis in colorectal cancer patients

  • 期刊论文

  • 发表日期：

    2025年4月23日

查看全文
  • Mitsunori Ushigome,
  • Hideaki Shimada,
  • Masaaki Ito,
  • Kimihiko Yoshida,
  • Takayuki Suzuki,
  • Satoru Kagami,
  • Yasuyuki Miura,
  • Tomoaki Kaneko,
  • Akiharu Kurihara,
  • Kimihiko Funahashi

摘要

Purpose

To evaluate the clinicopathological and prognostic significance of preoperative serum Midkine levels in patients with colorectal cancer.

Methods

Preoperative Midkine levels were analyzed using an enzyme-linked immunosorbent assay in 78 patients with colorectal cancer, at stages 0 (n = 2), I (n = 19), II (n = 25), III (n = 24), and IV (n = 8). Using a cut-off value of 421 pg/mL, the patients were divided into a Midkine(+) group and a Midkine(−) group. Clinicopathological factors and prognosis were compared between the two groups, using univariate and multivariate analyses.

Results

The overall positive rates were 46%, 32%, and 21% for CEA, Midkine, and CA19-9, respectively. The positive rate of the Midkine/CEA combination was 55%. The positive rates at stage 0/I were 19%, 19%, and 5% for CEA, Midkine, and CA19-9, respectively. The Midkine(+) group showed poor survival, but the differences were not significant. The Midkine (+)/CEA (+) group had significantly worse relapse-free survival (RFS) (p = 0.02). The Midkine (+)/CEA (+) level was an independent risk factor for RFS (p = 0.04) and overall survival (p = 0.03).

Conclusion

The Midkine (+)/CEA (+) combination may be an indicator of poor prognosis for patients with colorectal cancer.